Physician profile
Gilbert B Poon
NPI 1265465900
$12,293.21
in general payments reported to CMS, 2019-2025
37 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $1,567 · 2021: $4,046 · 2022: $2,033 · 2023: $898 · 2024: $1,027 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,170.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $2,350.02 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,748.42 | 2019-2025 | Breztri, Farxiga, Lokelma |
| Amgen INC. | $1,301.49 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $927.35 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Baxter Healthcare | $783.34 | 2022 | |
| Lilly USA, LLC | $779.02 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $666.89 | 2021-2025 | |
| Glaxosmithkline, LLC. | $454.93 | 2020-2025 | Trelegy Ellipta, Arexvy, Ojjaara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $405.13 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $351.16 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $347.26 | 2019-2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $342.58 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $226.09 | 2019-2025 | |
| Exact Sciences Corporation | $215.07 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $190.29 | 2019-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Poon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.